<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Liang P</submitter><funding>the Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University</funding><funding>Innovation Team of Sichuan Provincial Administration of Traditional Chinese Medicine</funding><funding>Sichuan Administration of Traditional Chinese Medicine</funding><funding>University-level project of Southwest Medical University</funding><funding>Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine</funding><pagination>7758</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9694973</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>27(22)</volume><pubmed_abstract>Toad venom, a dried product of secretion from &lt;i>Bufo bufo gargarizans&lt;/i> Cantor or &lt;i>Bufo melanostictus&lt;/i> Schneider, has had the therapeutic effects of hepatocellular carcinoma confirmed. Bufalin and cinobufagin were considered as the two most representative antitumor active components in toad venom. However, the underlying mechanisms of this antitumor effect have not been fully implemented, especially the changes in endogenous small molecules after treatment. Therefore, this study was designed to explore the intrinsic mechanism on hepatocellular carcinoma after the cotreatment of bufalin and cinobufagin based on untargeted tumor metabolomics. Ultraperformance liquid chromatography with tandem mass spectrometry (UHPLC-MS/MS) was performed to identify the absorbed components of toad ve</pubmed_abstract><journal>Molecules (Basel, Switzerland)</journal><pubmed_title>Uncovering the Mechanisms of Active Components from Toad Venom against Hepatocellular Carcinoma Using Untargeted Metabolomics.</pubmed_title><pmcid>PMC9694973</pmcid><funding_grant_id>2021ZKQN118</funding_grant_id><funding_grant_id>2020JC0150</funding_grant_id><funding_grant_id>2022C007</funding_grant_id><funding_grant_id>[2019] 119 and [2020] 33</funding_grant_id><funding_grant_id>ZYYCXTD-C-202207</funding_grant_id><pubmed_authors>Ren W</pubmed_authors><pubmed_authors>Liu Z</pubmed_authors><pubmed_authors>Yang L</pubmed_authors><pubmed_authors>Sun Q</pubmed_authors><pubmed_authors>Sun C</pubmed_authors><pubmed_authors>Ma Y</pubmed_authors><pubmed_authors>Liang P</pubmed_authors><pubmed_authors>Mao L</pubmed_authors><pubmed_authors>Mazhar M</pubmed_authors><pubmed_authors>Yang S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Uncovering the Mechanisms of Active Components from Toad Venom against Hepatocellular Carcinoma Using Untargeted Metabolomics.</name><description>Toad venom, a dried product of secretion from &lt;i>Bufo bufo gargarizans&lt;/i> Cantor or &lt;i>Bufo melanostictus&lt;/i> Schneider, has had the therapeutic effects of hepatocellular carcinoma confirmed. Bufalin and cinobufagin were considered as the two most representative antitumor active components in toad venom. However, the underlying mechanisms of this antitumor effect have not been fully implemented, especially the changes in endogenous small molecules after treatment. Therefore, this study was designed to explore the intrinsic mechanism on hepatocellular carcinoma after the cotreatment of bufalin and cinobufagin based on untargeted tumor metabolomics. Ultraperformance liquid chromatography with tandem mass spectrometry (UHPLC-MS/MS) was performed to identify the absorbed components of toad ve</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Nov</publication><modification>2025-04-26T05:19:51.671Z</modification><creation>2025-04-06T11:26:30.404Z</creation></dates><accession>S-EPMC9694973</accession><cross_references><pubmed>36431859</pubmed><doi>10.3390/molecules27227758</doi></cross_references></HashMap>